SCLERO.ORG is retiring 4-24-2021. Thank you for the memories! You'll still find us in the Wayback Machine, and we'll carry your stories in our hearts forever.
Scleroderma Newsroom
ISN News Manager: Jo Frowde
Media Stories
Scleroderma Archive
We maintain news archives for the most recent 3 years.
2019: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2021 - 2020 - 2019 - 2018

June 2019 Scleroderma News

Gastrointestinal manifestations on impaired quality of life in systemic sclerosis (SSc). Gastrointestinal involvement is frequent in SSc, with reflux or indigestion as the most common symptom. PubMed, J Dig Dis, 2019 May;20(5):256-261. (Also see Gastrointestinal Involvement and Quality of Life)

Anti-C1q autoantibodies (autoAbs) are frequently detected in patients with systemic sclerosis (SSc) associated with pulmonary fibrosis. Anti-C1q autoAbs were frequently detected in patients with SSc, and their high levels predict the co–occurrence of pulmonary fibrosis or pulmonary arterial hypertension. PubMed, Br J Dermatol, 03/15/2019. (Also see Pulmonary Fibrosis)

Capillaroscopy changes are associated with disease progression in patients with early systemic sclerosis (SSc): A prospective study. An active or a late pattern on capillaroscopy was an independent predictive risk factor for the development of SSc. PubMed, Int J Rheum Dis, 05/02/2019. (Also see Nailfold Videocapillaroscopy)

Distal radius and tibia bone microarchitecture impairment in female patients with diffuse systemic sclerosis (dSSc). Bone microarchitecture in patients with dSSc showed impairment of trabecular and cortical bone at distal radius and tibia and variables associated with hand involvement and disease duration may be considered prognostic factors of this bone impairment. PubMed, Osteoporos Int, 04/27/2019. (Also see Osteoporosis)

Chronic Q fever associated with Systemic Sclerosis (SSc). Chronic Q fever preceding SSc was associated with a milder course of SSc without the necessity of immunosuppressive drugs, while chronic Q fever development due to immunocompromised state was associated with a more deteriorating course of SSc. PubMed, Eur J Clin Invest, 2019 May 11:e13123. (Also see Systemic Autoimmune Rheumatic Diseases)

Interleukin-17 pathways in systemic sclerosis–associated fibrosis. There is multitude of evidence from across different tissues that interleukin-17 (IL-17) and its downstream pathways are strongly associated with the initiation and propagation of fibrosis. PubMed, Rheumatol Int, 05/09/2019. (Also see Interleukins and Skin Fibrosis)

Cytometric Characterization of Main Immunocompetent Cells in Patients with Systemic Sclerosis (SSc): Relationship with Disease Activity and Type of Immunosuppressive Treatment. In SSc patients, increment of T double positive and reduction of T double negative as well as natural killer and natural killer T cells were observed. PubMed, J Clin Med, 2019 May 8;8(5). (Also see Natural Killer Cells)

Validation of the REVEAL Prognostic Equation and Risk Score Calculator in Incident Systemic Sclerosis–Associated Pulmonary Arterial Hypertension. In predicting one–year survival in newly diagnosed SSc–PAH, the REVEAL prognostic equation and risk score provide very good discrimination but poor calibration. PubMed, Arthritis Rheumatol, 05/08/2019. (Also see Prognosis of Pulmonary Hypertension)

Patients with scleroderma require 'annual screening' for pulmonary arterial hypertension. Every patient with systemic sclerosis should be screened for pulmonary arterial hypertension every year, as early recognition, referral and aggressive treatment are necessary to improve long–term outcomes, according to Virginia Steen, MD. Healio Rheumatology, 05/22/2019. (Also see Pulmonary Hypertension Diagnosis)

Phase III study showed nintedanib slows the loss of pulmonary function in people living with systemic sclerosis associated interstitial lung disease (ILD). Results show that nintedanib slows the loss of pulmonary function in patients with SSc-ILD compared to placebo. Business Wire, 05/20/2019. (Also see Clinical Trials and Treatments for Pulmonary Fibrosis)

Go to Scleroderma Medical News: May 2019

SCLERO.ORG is the world's leading nonprofit for trustworthy research, support, education and awareness for scleroderma and related illnesses. We are a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team. Donations may also be mailed to:

International Scleroderma Network (ISN)
7455 France Ave So #266
Edina, MN 55435-4702 USA
Email [email protected]. Disclaimer. Privacy Policy.